AQX Pharma

AQX Pharma is an IP management platform developed by ANAQUA, designed specifically for pharmaceutical and life sciences companies. It focuses on the relationship between intellectual property and drug products across the full lifecycle of each, providing tools to enter, track, and link IP and drug data. The platform supports joint timeline views, revenue contribution analysis, and cost tracking to inform decisions across the organisation. AQX Pharma builds on the capabilities of ANAQUA's flagship platform, AQX Corporate, with additional data fields, meta fields, and pharma-specific tools.

The platform places the drug product at the centre of IP management, linking patents, trademarks, and licences to the products they protect. It is intended to help pharmaceutical companies manage market exclusivity, meet statutory reporting requirements, and understand the financial contribution of their IP portfolios.

Loss of Exclusivity Tracking

• Tracks important dates within the drug lifecycle, including Market Exclusivity End Date and Estimated Marketing Approval Date, providing visibility of IP and drug product readiness by country.
• Supports tracking of Patent Term Extensions and Supplemental Protection Certificates (SPCs) on a worldwide basis, as well as statutory registry listings such as the US FDA Orange Book, linked to both product and patent records.
• Provides access to a US Orange Book Analytics Report to view drug and patent lifecycle timelines for product planning or competitive analysis.

Statutory Reporting and Registry Compliance

• Includes built-in workflow alerts to help teams stay on top of country-specific registry deadlines.
• Prompts users for the exact data requirements needed for each country registry, reducing the risk of incomplete submissions.
• Reduces the effort involved in gathering registry information and allows reports to be accessed with a single click.

IP and Drug Lifecycle Integration

• Supports automated product-based workflows to address critical business processes and statutory requirements.
• Provides reports based on product lifecycle stage gates, such as clinical trials or market approval, to assess IP readiness at each stage.
• Integrates with PatSnap Synapse to access external pharmaceutical, chemical, and clinical trial information for use in stage gate reviews.
• Supports drug lifecycle management processes across growth, maturity, and decline phases, including virtual patent marking, patent box revenue reclaim, infringement management, new drug development, licensing, and divestiture.

IP Cost and Revenue Contribution Analysis

• Tracks and forecasts IP expenses in detail and generates IP contribution figures based on related drugs in each country, enabling comparison of expenditures against revenue.
• Reports on IP costs and related product IP contribution revenue, broken down by drug and country.
• Displays the revenue contribution of an individual patent across all drugs it supports.
• Aggregates individual patent contribution revenue to identify which patents or patent families generate the most contribution revenue.
• Identifies patents that may appear low-value on a per-drug basis but carry significance because they relate to multiple products.

AQX Pharma is offered as a dedicated platform for pharmaceutical IP teams, combining the core functionality of AQX Corporate with pharma-specific extensions. It supports integration with external data sources such as PatSnap Synapse and includes reporting tools aligned with US FDA Orange Book requirements and international registry obligations.